BIOMAT Database Logo BIOMAT Database Logo

Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma. 2024

Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
From the Centre Léon Bérard, Lyon, France.

A 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008187 Lutetium An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.
D008297 Male Males
D011868 Radioisotopes Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Daughter Isotope,Daughter Nuclide,Radioactive Isotope,Radioactive Isotopes,Radiogenic Isotope,Radioisotope,Radionuclide,Radionuclides,Daughter Nuclides,Daugter Isotopes,Radiogenic Isotopes,Isotope, Daughter,Isotope, Radioactive,Isotope, Radiogenic,Isotopes, Daugter,Isotopes, Radioactive,Isotopes, Radiogenic,Nuclide, Daughter,Nuclides, Daughter
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006573 Heterocyclic Compounds, 1-Ring Organic compounds that contain a ring structure made up of carbon and one or more additional elements such as nitrogen and oxygen. Heterocyclic Cpds, 1-Ring,1-Ring Heterocyclic Compounds,1-Ring Heterocyclic Cpds,Heterocyclic Compounds, 1 Ring,Heterocyclic Cpds, 1 Ring
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072078 Positron Emission Tomography Computed Tomography An imaging technique that combines a POSITRON-EMISSION TOMOGRAPHY (PET) scanner and a CT X RAY scanner. This establishes a precise anatomic localization in the same session. CT PET,CT PET Scan,PET CT Scan,PET-CT,PET-CT Scan,Positron Emission Tomography-Computed Tomography,CT PET Scans,CT Scan, PET,CT Scans, PET,PET CT Scans,PET Scan, CT,PET Scans, CT,PET-CT Scans,Scan, CT PET,Scan, PET CT,Scan, PET-CT,Scans, CT PET,Scans, PET CT,Scans, PET-CT
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
177 Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177 Lu-PSMA-I&T.
April 2023, Clinical nuclear medicine,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy.
September 2023, Journal of medicinal chemistry,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
October 2022, Journal of medicinal chemistry,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
Preclinical dosimetric studies of 177 Lu-scFvD2B and comparison with 177 Lu-PSMA-617 and 177 Lu-iPSMA endoradiotherapeutic agents.
July 2021, Medical physics,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry.
April 2023, Nuclear medicine communications,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
Peritoneal Metastases From Prostate Carcinoma Treated With 177 Lu-PSMA-I&T.
May 2023, Clinical nuclear medicine,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
April 2020, Molecular imaging and biology,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.
June 2016, Molecular imaging and biology,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
July 2016, Journal of labelled compounds & radiopharmaceuticals,
Valentin Pretet, and Anne Laure Giraudet, and Laure Vergnaud, and Emilie Paquet, and David Kryza
177 Lu-Microspheres Selective Intra-arterial Radionuclide Therapy : A Facile and Biocompatible Permanent Micro-Seed Implants for Unresectable Hepatocellular Carcinoma.
April 2024, Clinical nuclear medicine,
Copied contents to your clipboard!